Toutes les études
RecrutementOBSERVATIONNEL

A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems

This study is designed to help us understand more about liver problems that can happen in adults who have a genetic condition called Alpha-1 Antitrypsin Deficiency (AATD). When people have AATD, their body doesn't make enough of a special protein that protects the lungs and liver. This study will follow participants for five years to see how liver problems naturally develop and change over time without specific treatment. We also want to find out what might make these liver problems start or get worse, how doctors are currently diagnosing and monitoring them, and how AATD also affects adults' lung health. Participants will share their medical history and complete questionnaires each year.

En un coup d'œil

Statut
Recrutement
Sponsor
Takeda
Objectif d'inscription
500
Démarrer
25 Sep 2024
Achèvement estimé
31 Dec 2031

De quoi parle cette étude ?

This research study is all about understanding a genetic condition called Alpha-1 Antitrypsin Deficiency, or AATD. If you have AATD, your body doesn't produce enough of a protein called alpha-1 antitrypsin. This vital protein helps protect your lungs and liver. When there isn't enough of this protein, it can lead to health problems, especially in the liver and lungs.

The main goal of this study is to closely watch and learn about how liver problems develop and change over five years in adults with AATD who aren't receiving specific treatment for their liver condition. Think of it like observing the 'natural journey' of the disease. The study isn't testing a new medicine or treatment; instead, it's about gathering information to better understand the condition itself. Researchers also want to find out what factors might predict whether someone's liver condition will start, get better, or get worse. They will also look at how AATD is currently diagnosed and monitored in regular hospital care, and how it impacts an adult's lung function.

By taking part, you'd be helping doctors and researchers gain valuable knowledge about AATD and its effects on the liver and lungs. This information could, in the future, help improve how AATD is understood, diagnosed, and managed for other patients. It's about building a clearer picture of living with AATD.

Points clés

  • Study aims to understand AATD-related liver problems over 5 years.
  • No new treatments – it's an observational study.
  • Involves sharing medical history and annual questionnaires.
  • Helps researchers learn about the natural course of the condition.
  • Requires specific genetic types of AATD (Pi*ZZ or Pi*SZ).
  • Participation could improve future understanding and care for AATD patients.

Qui peut être éligible ?

To join this study, you need to be at least 18 years old. You must have a confirmed diagnosis of Alpha-1 Antitrypsin Deficiency (AATD). This includes specific genetic types of AATD, either called Pi*ZZ or Pi*SZ. If you have the Pi*SZ type, you also need to have moderate to severe liver disease that has been diagnosed through tests like a liver biopsy or other blood and imaging scans.

You cannot take part if you have certain other specific AATD genetic types. You also can't join if you've already had a liver transplant. If you've recently been part of another study testing a treatment for liver or lung disease, or are currently receiving a specific experimental treatment for AATD, you wouldn't be able to participate. Finally, if you haven't recently had certain liver tests done (like a biopsy, MRE, or FibroScan) and don't have plans to have one, you wouldn't be eligible.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Avez-vous 18 ans ou plus ?
  2. Do you have a confirmed diagnosis of Alpha-1 Antitrypsin Deficiency (AATD)?
  3. Have you been told you have the Pi*ZZ or Pi*SZ genetic type of AATD?
  4. If you have Pi*SZ AATD, do you also have moderate to severe liver disease?
  5. Have you NOT had a liver transplant?
  6. Are you NOT currently in another study testing a new liver or lung treatment?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you decide to take part in this study, you will be asked to share your medical history. This will include details about when your AATD was first identified and when any related liver or lung problems were diagnosed. At the beginning of the study, and then once every year for five years, you will be asked to fill out some questionnaires. These questionnaires are called 'patient-reported outcomes' and they ask about your health and how you are feeling. This study does not involve taking any new medications, having extra doctor visits beyond your usual care, or undergoing any special procedures. It's mainly about collecting information from your existing medical records and through these annual questionnaires for five years.

Risques et avantages potentiels

There is no direct medical benefit to you from taking part in this study, as it does not involve new treatments. However, your participation will provide valuable information that could help doctors better understand AATD and potentially improve care for others in the future. The risks of this study are very low, mainly involving the time spent completing questionnaires and the possibility that reviewing your medical records might uncover sensitive information. You are free to withdraw from the study at any time, for any reason, without it affecting your medical care.

Emplacements (8)

  • University of Florida
    Code postal vérifié
    Gainesville, États-Unis· Recrutement
  • University of South Carolina
    Code postal vérifié
    Charleston, United States· Recrutement
  • Vanderbilt University Medical Center
    Code postal vérifié
    Nashville, United States· Recrutement
  • Vienna General Hospital (AKH Wien)
    Code postal vérifié
    Vienne, Autriche· Recrutement
  • Universitätsklinikum Aachen
    Code postal vérifié
    Aix-la-Chapelle, Allemagne· Recrutement
  • Beaumont Hospital
    Code postal vérifié
    Dublin, Ireland· Recrutement
  • Hospital Universitari Vall d'Hebron
    Code postal vérifié
    Barcelona, Spain· Recrutement
  • Hôpital Queen Elizabeth de Birmingham
    Code postal vérifié
    Birmingham, United Kingdom· Recrutement

Questions fréquentes

What is Alpha-1 Antitrypsin Deficiency (AATD)?

It's a genetic condition where your body doesn't make enough of a protein that protects your lungs and liver, which can lead to health problems.

Vais-je recevoir un nouveau traitement dans cette étude ?

No, this study does not involve any new treatments or medicines. It's about observing the condition's natural progression.

Combien de temps dure l'étude ?

You would be part of the study for five years, providing information once a year.

Participer affectera-t-il mes soins médicaux réguliers ?

No, this study is designed to fit in with your usual medical care and should not affect it.

What do 'Pi*ZZ' or 'Pi*SZ' mean?

These are specific genetic types of AATD. The study is looking for people with one of these particular genetic makeups.

Comment en savoir plus

Takeda Contact

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Intéressé à participer ?

Inscrivez votre intérêt

Partagez vos coordonnées et l'équipe de recherche pour "A Study in Adults to Learn About Inherited Alpha-1 Antitryps… vous contactera si vous êtes éligible. Consultez toujours votre médecin avant d'accepter de participer.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.